Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 2/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CPA3 | P15088 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4197623 | 0.85 | TRPA1 (0.54) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL10521135 | 0.85 | TRPA1 (0.54) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL4223754 | 0.81 | CPA3 (0.62) | CYP1A2CPA1CPB1CPA3CPB2 | |
| SCHEMBL4223751 | 0.81 | CPA3 (0.62) | CYP1A2CPA1CPB1CPA3CPB2 | |
| SCHEMBL1062345 | 0.79 | SIGMAR1 (0.43) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL8634822 | 0.79 | SIGMAR1 (0.47) | SIGMAR1MAOASLC6A3 | |
| SCHEMBL527616 | 0.79 | HTR2A (0.48) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL6545341 | 0.78 | EPHX1 (0.64) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL9865430 | 0.78 | EPHX1 (0.50) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL10567690 | 0.78 | SIGMAR1 (0.58) | EPHX1TAAR1SLC6A2SIGMAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582660-B2 | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | C-A-I-R BIOSCIENCES GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-20060235054-A1 | 2-Thio-substituted imidazole derivatives and their use in pharmaceutics | MERCKLE-GMBH (DE) | 2006-10-19 | — | — | US | disclosed |
| EP-0763053-A4 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORP (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5760025-A | ADMINISTERING TESTOSTERONE 5A-REDUCTASE INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 1998-06-02 | — | — | US | disclosed |
| US-5717088-A | REACTING WITH A CYANOPHOSPHATE IN THE PRESENCE OF AN ALKALI METAL CYANIDE | SANKYO COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| US-5698720-A | INTERMEDIATES FOR TESTOSTERONE 5-ALPHA-REDUCTASE INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0567271-B1 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO CO (JP) | 1997-07-02 | — | — | EP | disclosed |
| EP-0763053-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0725074-A2 | Compounds suitable for use as intermediates in the preparation of Androst-3,5-dien-3-carboxy derivatives | SANKYO COMPANY LIMITED (JP) | 1996-08-07 | — | — | EP | disclosed |
| US-5536714-A | Steroid derivatives for the treatment of prostatic hypertrophy their preparation and uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-16 | — | — | US | disclosed |
| EP-0484094-B1 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO CO (JP) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995033761-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-14 | — | — | WO | disclosed |
| US-5302621-A | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1994-04-12 | — | — | US | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235054-A1 | 2-Thio-substituted imidazole derivatives and their use in pharmaceutics | IL2, TPMT, IFNG | EPHX1 2459/4885TAAR1 342/4885SLC6A2 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.